Abstract library

80 results for "whole exome".
#1461 Whole Exome Sequencing of Three Families with Small Intestine Neuroendocrine Tumors
Introduction: Small intestine neuroendocrine tumors (siNETs) are the most prevalent small intestine neoplasms. However, familial siNETs are rarely described.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Matthias Beyens
#775 Whole Exome Sequence Of BON-1 And QGP-1, Two Human Pancreatic Neuroendocrine Tumor Cell Lines, Reveals Homozygous Loss Of Function Mutations In TP53, HRNR and CYFIP2.
Introduction: The human BON-1 and QGP-1 cell lines are two models often used in pancreatic neuroendocrine tumor (PNET) research. Data on protein-changing mutations in these cell lines is lacking.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Timon Vandamme
#2293 Genomic and Transcriptomic Characterization of Aggressive Well Differentiated Pancreatic Neuroendocrine Tumors (WD PanNET)
Introduction: While the genomic and transcriptomic landscape of low proliferating PanNET have been well studied, pathways driving aggressive WD PanNET are still unclear.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Jerome Cros
#658 Somatic Mutations in H-RAS in Sporadic Pheochromocytoma and Paraganglioma Identified by Exome Sequencing.
Introduction: Up to 60% of pheochromocytoma (PCC) and paraganglioma (PGL) are associated with mutations in established PCC and PGL susceptibility loci. A majority of unexplained cases are characterized by an increased activity of the RAS/RAF/ERK signalling pathway. Mutations in RAS subtypes H, K and N are common in human cancers, however, previous studies have been inconsistent regarding the mutational status of RAS in PCC and PGL.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Joakim Crona
#977 Inducing, Understanding and Overcoming Resistance to Everolimus in Pancreatic Neuroendocrine Tumors
Introduction: Treatment with the mTOR-inhibitor everolimus improves progression-free survival in advanced pancreatic neuroendocrine tumors (PNETs). However, adaptive resistance to mTOR inhibition is described.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Timon Vandamme
Keywords: everolimus
#1672 PD-L1 Expression and Quantitative Assessment of Tumor-Infiltrating T Cell Subsets in Carcinoid Tumors and Large Cell Neuroendocrine Carcinomas of the Lung
Introduction: Little is known about the expression of PD-L1 an the immune infiltrate in neuroendocrine neoplasms of the lung.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Dr Julien Hadoux
#856 DAXX and ATRX Loss Defines Chromosomal Instability and Poor Outcome in Pancreatic NET
Introduction: Chromosomal Instability (CIN) has been reported in pancreatic neuroendocrine tumors (pNETs) with poor outcome. However, no specific genetic background has been associated with CIN. Whole exome sequencing revealed mutations in DAXX (Death domain associated protein gene) and ATRX (ATR-X gene) in 40% of pNETs. DAXX and ATRX mutations in pNETs are associated with Alternative Lengthening of Telomeres (ALT) activation.
Conference: 11th Annual ENETS Conference (2014)
Category: ...none of the below
Presenting Author: PhD Ilaria Marinoni
Keywords: pNET, Daxx, Atrx, ALT, CIN
#2113 How to Perform Contrast Enhanced Oncologic Staging MRI of Abdomen and Pelvis with a Hepatocyte Specific Agent in a Large Bore MR Scanner: Optimizing Extrahepatic Tumor Evaluation in Neuroendocrine Neoplasms
Introduction: Liver specific MR contrast agents in neuroendocrine neoplasms (NEN) have shown its advantages in evaluation of hepatic tumor burden. However, a standard scan protocol is insufficient in extrahepatic and especially pelvic tumor evaluation.
Conference: 15th Annual ENETS conference (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr. Uli Fehrenbach
#2196 The Neuroendocrine Phenotype, Genomic Profile, and Therapeutic Sensitivity of GEPNET Cell Lines
Introduction: Patient tumour-derived cell lines have been widely used for studying the molecular mechanisms of tumours and their response to therapy. The establishment of cell lines from gastro-entero-pancreatic neuroendocrine tumours (GEPNETs) has proved difficult, but despite the challenges a limited amount of cell lines now exists.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Tobias Hofving
#722 Isolation and Whole Genome Amplification of Single Circulating Tumor Cells in Neuroendocrine Tumors: A Pilot Study
Introduction: We have previously demonstrated that Circulating Tumor Cells (CTCs) can be detected in patients with neuroendocrine tumors (NET) and that their presence is prognostic. Downstream analysis of CTCs provides an opportunity to explore their potential as biomarker for targeted therapy. Here we present initial data which demonstrates that molecular profiling can be successfully performed on single CTCs from patients with NETs
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Dalvinder Mandair